Barriers to progress - The impact of tolerability problems

Daniel Casey

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Side-effects of antipsychotic treatment are important factors in patients' compliance with treatment regimens. Of particular relevance to compliance are extrapyramidal symptoms (EPS), sedation, weight gain and sexual dysfunction. The new, atypical antipsychotics offer several tolerability benefits over conventional neuroleptics, particularly with respect to EPS. However, differences in their receptor binding characteristics result in different side-effect profiles. All novel antipsychotics have a high 5-HT2 to D2 receptor binding ratio, which is postulated to be important for a low liability for EPS. Ziprasidone, a new antipsychotic in the late stages of clinical development, has a low affinity for some receptor types, activation of which has been linked with adverse events such as sedation, postural hypotension, weight gain and cognitive impairment; for example, ziprasidone has minimal activity at muscarinic (M1), histaminergic (H1) and α1-adrenergic receptors. In short- and long-term clinical trials, ziprasidone had a low liability for side-effects typically associated with poor compliance, such as EPS, weight gain and sexual dysfunction. The tolerability profiles of the new antipsychotics represent a major improvement over the older neuroleptics. The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes.

Original languageEnglish (US)
JournalInternational Clinical Psychopharmacology
Volume16
Issue numberSUPPL. 1
StatePublished - 2001
Externally publishedYes

Fingerprint

Antipsychotic Agents
Weight Gain
Orthostatic Hypotension
Patient Compliance
Adrenergic Receptors
Cholinergic Agents
Compliance
Therapeutics
Odds Ratio
Clinical Trials
Pharmaceutical Preparations
ziprasidone

Keywords

  • Antipsychotics
  • Compliance
  • Side-effects
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Barriers to progress - The impact of tolerability problems. / Casey, Daniel.

In: International Clinical Psychopharmacology, Vol. 16, No. SUPPL. 1, 2001.

Research output: Contribution to journalArticle

@article{da2cb77d232944a4acd11a147dae26ef,
title = "Barriers to progress - The impact of tolerability problems",
abstract = "Side-effects of antipsychotic treatment are important factors in patients' compliance with treatment regimens. Of particular relevance to compliance are extrapyramidal symptoms (EPS), sedation, weight gain and sexual dysfunction. The new, atypical antipsychotics offer several tolerability benefits over conventional neuroleptics, particularly with respect to EPS. However, differences in their receptor binding characteristics result in different side-effect profiles. All novel antipsychotics have a high 5-HT2 to D2 receptor binding ratio, which is postulated to be important for a low liability for EPS. Ziprasidone, a new antipsychotic in the late stages of clinical development, has a low affinity for some receptor types, activation of which has been linked with adverse events such as sedation, postural hypotension, weight gain and cognitive impairment; for example, ziprasidone has minimal activity at muscarinic (M1), histaminergic (H1) and α1-adrenergic receptors. In short- and long-term clinical trials, ziprasidone had a low liability for side-effects typically associated with poor compliance, such as EPS, weight gain and sexual dysfunction. The tolerability profiles of the new antipsychotics represent a major improvement over the older neuroleptics. The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes.",
keywords = "Antipsychotics, Compliance, Side-effects, Tolerability",
author = "Daniel Casey",
year = "2001",
language = "English (US)",
volume = "16",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Barriers to progress - The impact of tolerability problems

AU - Casey, Daniel

PY - 2001

Y1 - 2001

N2 - Side-effects of antipsychotic treatment are important factors in patients' compliance with treatment regimens. Of particular relevance to compliance are extrapyramidal symptoms (EPS), sedation, weight gain and sexual dysfunction. The new, atypical antipsychotics offer several tolerability benefits over conventional neuroleptics, particularly with respect to EPS. However, differences in their receptor binding characteristics result in different side-effect profiles. All novel antipsychotics have a high 5-HT2 to D2 receptor binding ratio, which is postulated to be important for a low liability for EPS. Ziprasidone, a new antipsychotic in the late stages of clinical development, has a low affinity for some receptor types, activation of which has been linked with adverse events such as sedation, postural hypotension, weight gain and cognitive impairment; for example, ziprasidone has minimal activity at muscarinic (M1), histaminergic (H1) and α1-adrenergic receptors. In short- and long-term clinical trials, ziprasidone had a low liability for side-effects typically associated with poor compliance, such as EPS, weight gain and sexual dysfunction. The tolerability profiles of the new antipsychotics represent a major improvement over the older neuroleptics. The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes.

AB - Side-effects of antipsychotic treatment are important factors in patients' compliance with treatment regimens. Of particular relevance to compliance are extrapyramidal symptoms (EPS), sedation, weight gain and sexual dysfunction. The new, atypical antipsychotics offer several tolerability benefits over conventional neuroleptics, particularly with respect to EPS. However, differences in their receptor binding characteristics result in different side-effect profiles. All novel antipsychotics have a high 5-HT2 to D2 receptor binding ratio, which is postulated to be important for a low liability for EPS. Ziprasidone, a new antipsychotic in the late stages of clinical development, has a low affinity for some receptor types, activation of which has been linked with adverse events such as sedation, postural hypotension, weight gain and cognitive impairment; for example, ziprasidone has minimal activity at muscarinic (M1), histaminergic (H1) and α1-adrenergic receptors. In short- and long-term clinical trials, ziprasidone had a low liability for side-effects typically associated with poor compliance, such as EPS, weight gain and sexual dysfunction. The tolerability profiles of the new antipsychotics represent a major improvement over the older neuroleptics. The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes.

KW - Antipsychotics

KW - Compliance

KW - Side-effects

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0035110191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035110191&partnerID=8YFLogxK

M3 - Article

VL - 16

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - SUPPL. 1

ER -